Furthermore, CypB’s PPIase activity affects lipid metabolism through key pathways including AKT/mTOR and IRE1α-XBP1, helping to prevent and treat obesity-related metabolic disorders such as diabetes and hyperlipidemia. Here, AKT1 is linked to metabolic disease.